Logo image of TERN

TERNS PHARMACEUTICALS INC (TERN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:TERN - US8808811074 - Common Stock

34.33 USD
-1.64 (-4.56%)
Last: 1/23/2026, 8:00:00 PM
35.307 USD
+0.98 (+2.85%)
After Hours: 1/23/2026, 8:00:00 PM
Fundamental Rating

3

Taking everything into account, TERN scores 3 out of 10 in our fundamental rating. TERN was compared to 191 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for TERN as it has an excellent financial health rating, but there are worries on the profitability. TERN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • TERN had negative earnings in the past year.
  • TERN had a negative operating cash flow in the past year.
  • In the past 5 years TERN always reported negative net income.
  • In the past 5 years TERN always reported negative operating cash flow.
TERN Yearly Net Income VS EBIT VS OCF VS FCFTERN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • The Return On Assets of TERN (-31.31%) is comparable to the rest of the industry.
  • The Return On Equity of TERN (-33.24%) is better than 60.73% of its industry peers.
Industry RankSector Rank
ROA -31.31%
ROE -33.24%
ROIC N/A
ROA(3y)-26.35%
ROA(5y)-28.14%
ROE(3y)-27.6%
ROE(5y)-31.38%
ROIC(3y)N/A
ROIC(5y)N/A
TERN Yearly ROA, ROE, ROICTERN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

1.3 Margins

  • TERN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TERN Yearly Profit, Operating, Gross MarginsTERN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K -5K

8

2. Health

2.1 Basic Checks

  • TERN has more shares outstanding than it did 1 year ago.
  • TERN has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for TERN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TERN Yearly Shares OutstandingTERN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
TERN Yearly Total Debt VS Total AssetsTERN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • TERN has an Altman-Z score of 108.21. This indicates that TERN is financially healthy and has little risk of bankruptcy at the moment.
  • TERN has a better Altman-Z score (108.21) than 98.95% of its industry peers.
  • TERN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 108.21
ROIC/WACCN/A
WACCN/A
TERN Yearly LT Debt VS Equity VS FCFTERN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 19.52 indicates that TERN has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 19.52, TERN belongs to the best of the industry, outperforming 89.01% of the companies in the same industry.
  • A Quick Ratio of 19.52 indicates that TERN has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 19.52, TERN belongs to the best of the industry, outperforming 89.01% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 19.52
Quick Ratio 19.52
TERN Yearly Current Assets VS Current LiabilitesTERN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

0

3. Growth

3.1 Past

  • TERN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.71%, which is quite good.
EPS 1Y (TTM)12.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -4.19% on average over the next years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y2.11%
EPS Next 2Y-7.13%
EPS Next 3Y-9.79%
EPS Next 5Y-4.19%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TERN Yearly Revenue VS EstimatesTERN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
TERN Yearly EPS VS EstimatesTERN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TERN. In the last year negative earnings were reported.
  • Also next year TERN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TERN Price Earnings VS Forward Price EarningsTERN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TERN Per share dataTERN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

  • A cheap valuation may be justified as TERN's earnings are expected to decrease with -9.79% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.13%
EPS Next 3Y-9.79%

0

5. Dividend

5.1 Amount

  • No dividends for TERN!.
Industry RankSector Rank
Dividend Yield 0%

TERNS PHARMACEUTICALS INC / TERN FAQ

Can you provide the ChartMill fundamental rating for TERNS PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 3 / 10 to TERN.


What is the valuation status of TERNS PHARMACEUTICALS INC (TERN) stock?

ChartMill assigns a valuation rating of 0 / 10 to TERNS PHARMACEUTICALS INC (TERN). This can be considered as Overvalued.


How profitable is TERNS PHARMACEUTICALS INC (TERN) stock?

TERNS PHARMACEUTICALS INC (TERN) has a profitability rating of 1 / 10.


What is the financial health of TERNS PHARMACEUTICALS INC (TERN) stock?

The financial health rating of TERNS PHARMACEUTICALS INC (TERN) is 8 / 10.